TCT- 610 Prospective, Multi-Center Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and 2-Year Clinical Results

Abizaid, Alexandre; Schofer, Joachim; Mæng, Michael; Witzenbichler, Bernhard; Botelho, Roberto; Ormiston, John A.; Costa, Ricardo; Costa, José de Ribamar; Chamié, Daniel; Abizaid, Andréa; Yan, John; Bbhat, Vinayak; Morrison, Lynn; Toyloy, Sara; Verheye, Stefan

doi:10.1016/j.jacc.2014.07.676

Cited by 10 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The findings are generally encouraging confirming favorable antirestenotic efficacy outside the setting of a clinical trial. For example, in‐stent LLL in our study was 0.26 ± 0.51 mm at a median of 196 days, which is broadly comparable with the measurements from the ABSORB Cohort B trial (LLL of 0.16 ± 0.18 mm at 6 months) and with a novolimus‐eluting BRS (LLL of 0.21 ± 0.34 mm after 6 months) . In addition, a recent randomized clinical trial—EVERBIO‐II—reported a LLL of 0.28 ± 0.39 mm at 9 months in patients treated with everolimus‐eluting BRS .…”

Section: Discussionsupporting

confidence: 86%

Angiographic and clinical outcomes of patients treated with everolimus‐eluting bioresorbable stents in routine clinical practice: Results of the ISAR‐ABSORB registry

Hoppmann

Kufner

Cassese

et al. 2015

Cathet Cardio Intervent

View full text Add to dashboard Cite

The use of everolimus-eluting BRS in routine clinical practice is associated with high antirestenotic efficacy in patients undergoing angiographic surveillance. Overall clinical outcomes at 12 months are satisfactory though stent thrombosis rates are not insignificant. Further study with longer term follow-up and larger numbers of treated patients is required before we can be sure of the role of these devices in clinical practice.

show abstract

Section: Discussionsupporting

confidence: 86%

Angiographic and clinical outcomes of patients treated with everolimus‐eluting bioresorbable stents in routine clinical practice: Results of the ISAR‐ABSORB registry

Hoppmann

Kufner

Cassese

et al. 2015

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…The Amaranth FORTITUDE stent successfully completed clinical trials and further studies for the second-generation FORTITUDE stent are planned [13]. Elixir DESolve and REVA Fantom completed first-in-man trials and additional clinical trials involving >100 patients [14,15]. In contrast, there are no clinical performance progress reports published recently on the Arterial Remodelling Technologies (ART) stent or the first fully bioabsorable stent, the Igaki-Tamai stent.…”

Section: Introductionmentioning

confidence: 99%

Experimental mechanical testing of Poly (l-Lactide) (PLLA) to facilitate pre-degradation characteristics for application in cardiovascular stenting

et al. 2016

View full text Add to dashboard Cite

Next-generation stents made from Biodegradable Polymers (BPs) aim to address the long-term risks (i.e. late restenosis and in-stent thrombosis) associated with both Bare Metal Stents and Drug Eluting Stents, whilst aiming to reduce the healthcare costs associated with secondary care. However, the true potential of BPs for cardiovascular load bearing applications does not appear to be fully realised. While the literature provides data on stiffness and strength of BPs, it is lacking pre-degradation experimental data on the recovery behaviour and temperature and strain rate dependency. In this paper, an experimental study is undertaken to address this knowledge gap using Poly (L-Lactide) (PLLA) samples, subjected to tensile testing. Stressstrain characteristics, recovery, relaxation and creep data at body temperature are reported and considered in the context of real-life stent deployment. The experimental data herein reveal a strong temperature and strain rate dependency, whilst demonstrating associated plasticity within the material. The work provides a physical evaluation of PLLA's pre-degradation behaviour, establishing key data points to allow the assessment of PLLA as a viable material in the wider context of stent deployment and load carrying capacity.

show abstract

“…Therefore, BDSs have better biocompatibility and fewer complications. However, there are still some problems in the development of BDSs, especially weak mechanical properties and unclear degradation behavior [22][23][24], so that the long-term efficacy and safety of the BDSs are still under further research.…”

Section: Introductionmentioning

confidence: 99%

A Review on Manufacturing and Post-Processing Technology of Vascular Stents

et al. 2022

View full text Add to dashboard Cite

Percutaneous coronary intervention (PCI) with stent implantation is one of the most effective treatments for cardiovascular diseases (CVDs). However, there are still many complications after stent implantation. As a medical device with a complex structure and small size, the manufacture and post-processing technology greatly impact the mechanical and medical performances of stents. In this paper, the development history, material, manufacturing method, and post-processing technology of vascular stents are introduced. In particular, this paper focuses on the existing manufacturing technology and post-processing technology of vascular stents and the impact of these technologies on stent performance is described and discussed. Moreover, the future development of vascular stent manufacturing technology will be prospected and proposed.

show abstract

TCT- 610 Prospective, Multi-Center Evaluation of the DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and 2-Year Clinical Results

Cited by 10 publications

References 0 publications

Angiographic and clinical outcomes of patients treated with everolimus‐eluting bioresorbable stents in routine clinical practice: Results of the ISAR‐ABSORB registry

Angiographic and clinical outcomes of patients treated with everolimus‐eluting bioresorbable stents in routine clinical practice: Results of the ISAR‐ABSORB registry

Experimental mechanical testing of Poly (l-Lactide) (PLLA) to facilitate pre-degradation characteristics for application in cardiovascular stenting

A Review on Manufacturing and Post-Processing Technology of Vascular Stents

Contact Info

Product

Resources

About